Transfusion in autologous and allogenic hematopoietic stem cell transplant: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Affiliation auteurs!!!! Error affiliation !!!!
TitreTransfusion in autologous and allogenic hematopoietic stem cell transplant: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Type de publicationJournal Article
Year of Publication2019
AuteursGiraud C, Thibert J-B, Desbrosses Y, Debiol B, Alsuliman T, Bardiaux L, Garban F, Huynh TNgoc Phuon, Samsonova O, Yakoub-Agha I, Bruno B
JournalBULLETIN DU CANCER
Volume106
PaginationS52-S58
Date PublishedJAN
Type of ArticleArticle
ISSN0007-4551
Mots-clésAllogeneic hematopoietic, Blood component therapy, Cellular immunotherapy, SFGM-TC, stem cell transplantation
Résumé

The recommendations of the French Health and Drug Safety Authorities (HAS/ANSM-Haute Autorite de sante/Agence nationale de securite du medicament) ore known, but there ore always new developments underway. With regards to CMV suppression, there is the introduction of platelet glycoprotein la and the Intercept (Amotosalem + UVA) inactivation method which addresses bacterial risk. The irradiation of platelets is included in the recommendations to ensure HEV-negative plasma post allograft. In terms of blood transfusion safety, these measures as well as the brooder spectrum of la, particularly for arboviruses, ore o real breakthrough. The survey conducted in clinical services and the services providing blood products for transfusion along with a literature review have shown that several improvements need to be made. The first is a reduction of transfusions of concentrated red blood cells with introduction at o threshold of 7 g/dL during hospitalization of patients without a fragile clinical status. The second improvement would address transfusion of refractory thrombocytopenia, encouraging an increase in discussion between clinicians and those conducting the transfusion in order to consider different etiologies and to identify appropriate core protocols. Third would be the need for the transmission of information between the transplantation doctors and blood transfusion specialists in order to define on approach to transfusion care adopted to the patient's situation. It is important to inform and educate patients about transfusion protocols post allotransplant or autotransplant. It must be clearly communicated to patients that they should always hove on their person their blood group documentation. This is especially true when receiving care for a hemopathy or on autologous transplant. If undergoing an allogeneic transplant, patients should also carry transfusion guidelines post autotransplant or post allotransplant along with the phone numbers for the stem cell transplantation deportment and the blood transfusion center responsible for their care.

DOI10.1016/j.bulcan.2018.08.016